Slide 1: Oriola Corporation Financial Statements 2020
Oriola Corporation Financial Statements 2020
Slide 2: Introduction: Juko Hakala
Introduction: Juko Hakala Juko Hakala was appointed Oriola's Interim President and CEO on February 1st, 2021. The recruitment process to find a new CEO is started. Juko has extensive experience in CEO and other leadership positions in listed companies in Finland and in the Nordic countries. He is al
Slide 3: Q4 2020 highlights
Q4 2020 highlights ”Positive quarter in an exceptional year” • The pandemic continued to impact Oriola’s operating environment negatively • Pharmaceutical volumes declined and net sales increased 1.5 % in constant currency • Strong online sales in Consumer, 107% vs. market growth of 66% • Profitabil
Slide 4: 2020 highlights
2020 highlights 2020 highlights ”Delivering our purpose ”Health for life” ”Yearinof anthe exceptional pandemic” year” • The pandemic had a significant impact on • Oriola’s The pandemic operatinghadenvironment a significantand impact on Oriola’s operating environment and operations. operations. • Pha
Slide 5: Key figures
Key figures continuing operations Invoicing Net sales Adjusted EBIT1 EUR million EUR million EUR million 4 000 2 000 70 3 733 3 765 3 518 1 801 3 500 3 364 3 336 1 721 58.7 60 979 987 1 589 1 552 1 528 466 3 000 929 1 500 447 859 872 50 15.0 411 395 395 2 500 917 915 40 39.0 844 439 34.4 812 823 429
Slide 6: Adjusted EBIT
Adjusted EBIT Adjusted EBIT1 Adjusted EBIT development1 EUR million EUR million 10 10 8 8 1.3 6 6 1.5 9.1 -0.1 4 8.0 4 3.3 8.0 6.9 6.3 5.6 2 3.7 2 2.1 2.1 0 -0.3 0 2019 Consumer Pharma Retail Group 2020 2019 2019 2019 2019 2020 2020 2020 2020 Q4 items Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1The figures for Q1-Q
Slide 7: Operating environment
& Oriola Operating environment
Slide 8: Consumer markets
Consumer markets Online pharmacy market Market shares Pharmacy 388 market size in Sweden BSEK 3 397 2 1 49 BSEK 49 BSEK 0 2017 Q1 2017 Q2 2017 Q3 2017 Q4 2018 Q1 2018 Q2 2018 Q3 2018 Q4 2019 Q1 2019 Q2 2019 Q3 2019 Q4 2020 Q1 2020 Q2 2020 Q3 2020 Q4 Oriola online market share 8% 7% Oriola/Kronans Ap
Slide 9: Wholesale markets
Wholesale markets Pharmaceutical market volume declined in Q4 Pharmaceutical market value growth in Q4: Finland +1.9% and Sweden +3.0% Finland Wholesale Sweden Wholesale 2.8 BEUR 49 BSEK Oriola 42% (47%) Oriola 47% (47%) Others 58% (53%) Others 53% (53%) Market shares are quarterly Source: LTK and O
Slide 10: Retail markets
Retail markets Market share dose dispensing TG/OTC products supply for pharmacies in Sweden Sweden Total 230,000 Oriola 43% (43%) Others 57% (57%) 25% patients from the total market of EUR 1.3 billion Market share is quarterly figure and market size rolling 12 month figure Finland Staffing services
Slide 11: Business Area reviews Q4 2020
Business Area reviews Q4 2020
Slide 12: Three customer-centric business areas
Three customer-centric business areas Consumer business area Pharma business area Retail business area Pharmacy services and products for Tailored logistics, expert and advisory A wide range of health and wellbeing consumer health and wellbeing in Sweden services for pharmaceutical companies, produc
Slide 13: Consumer Q4 2020
Consumer Q4 2020 • Net sales increased by 2.6% to 195.8 M€ Adjusted EBIT1 EUR million in constant currency 6 • Strong growth continued in online sales (+107% vs market +66%) 5 • Pharmacy volumes decreased especially in 4 shopping centres 3 5.4 • Share of OTC and traded goods of net sales 4.9 4.4 2 4
Slide 14: Pharma Q4 2020
Pharma Q4 2020 Adjusted EBIT EUR million • Net Sales increased by 3.0% to 249.4 M€, and increased by 0.7% in constant 6 currency 5 • Pharmaceutical volumes slowed down due 4 to the pandemic. 3 • Profit negatively impacted by changes in 5.2 4.7 customer agreements 2 3.5 4.2 3.6 4.1 3.0 1 2.1 0 2019 2
Slide 15: Retail Q4 2020
Retail Q4 2020 Adjusted EBIT • Net sales increased by 8.7% to EUR million 124.0 M€, and increased by 5.3% in constant currency 1 • Demand for products related to the 1.5 pandemic remained active 0.7 • Improved profitability in dose 0.2 0.3 0.2 dispensing impacted results positively 0 -0.3 -0.6 -0.8
Slide 16: Financial review Q4 2020
& Oriola Financial review Q4 2020
Slide 17: Invoicing and net sales
Invoicing and net sales Invoicing Invoicing Net sales EUR million EUR million 1 000 500 900 450 800 400 700 350 600 300 500 942 979 965 987 250 466 894 917 898 915 448 429 447 460 436 439 400 979 200 397 300 150 200 100 100 50 0 0 2019 2019 2019 2019 2020 2020 2020 2020 2019 2019 2019 2019 2020 2020
Slide 18: Adjusted EBIT
Adjusted EBIT Adjusted EBIT1 Adjusted EBIT development1 EUR million EUR million 10 10 8 8 1.3 6 6 1.5 9.1 -0.1 4 8.0 4 8.0 6.9 3.3 5.6 6.3 2 3.7 2 2.1 2.1 0 0 -0.3 2019 Consumer Pharma Retail Group 2020 2019 2019 2019 2019 2020 2020 2020 2020 Q4 items Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1The figures for Q1-Q
Slide 19: Profit for the period and earnings per share
Profit for the period and earnings per share Profit for the period1 Earnings per share1 EUR million EUR 6 0.06 4 0.04 5.1 2 4.5 4.1 0.02 3.7 0.02 0.03 1.7 2.0 0.02 0.02 0.01 0.01 0 0.00 -0.2 -0.00 -0.01 -1.6 -2 -0.02 2019 2019 2019 2019 2020 2020 2020 2020 2019 2019 2019 2019 2020 2020 2020 2020 Q1
Slide 20: Cash flow
Cash flow Quarterly net cash flow from operating activities Q4 YTD 2020 change in cash EUR million EUR million 80 200 60 150 40 70.4 70 -31.4 48 46 20 100 58.3 27 168.2 13 9 0 -1 4 50 -25 -20 70.8 -40 0 2018 2019 2019 2019 2019 2020 2020 2020 2020 Cash Q4 2019 Operating Investing Financing Cash Q4 2
Slide 21: Net Interest-Bearing Debt
Net Interest-Bearing Debt Net interest-bearing debt 31 Dec 31 Dec EUR million EUR million 2020 2019 250 Bank loans 117.9 57.8 (syndicated Bank & term) 200 Commercial papers 78.6 35.0 Advance payment from pharmacies 17.0 13.2 150 Lease liabilities 81.7 84.3 100 199 Cash and cash equivalents 168.2 70
Slide 22: Q4 2020 Key take-aways
Q4 2020 Key take-aways ”Positive quarter in an exceptional year” Continued Pharmaceutical Strong online Profitability Delivering our pandemic impact volumes declined sales in Consumer developed purpose to Oriola’s favourably in “Health for life” operating many areas environment In 2021 we continue t
Slide 23: Outlook for 2021
Outlook for 2021 Adjusted EBIT on a constant currency basis stays on the same level or increases from the 2020 level The COVID-19 pandemic is expected to continue during 2021. Severity and duration of the pandemic remain unclear in Oriola’s operating environment. Oriola’s business outlook is based o
Slide 24: Capital Markets Day: Save the Date 25.11.2021
Capital Markets Day: Save the Date 25.11.2021 Oriola will organise a Capital Markets Day on 25.11.2021. Invitation and more information will follow closer to the event. 24
Slide 25: Thank you!
Thank you! Our next events: 16/3/2021 Oriola Corporation’s Annual General Meeting 27/4/2021 Interim Report 1-3/2021 20/7/2021 Half year financial report 1-6/2021 27/10/2021 Interim Report 1-9/2021 25/11/2021 Capital Markets Day IR contact: Katja Graff, Treasury & IR Manager, +358 10 429 013 or katja